Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma von Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

Volltext

114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers von King, G., Cohen, S.A., Chiorean, E.G., Harris, W.P., Yeung, R., Park, J., Zhen, D.B., Coveler, A.L., Diehl, A., Safyan, R., Jurdi, A., Brdiges, C.

Volltext

990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC) von Galle, P.R., Kim, R.D., Sung, M.W., Harris, W.P., Waldschmidt, D., Cabrera, R., Mueller, U., Nakajima, K., Ishida, T., El-Khoueiry, A.B.

Volltext

LBA21 Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study) von Mulcahy, M.F., Salem, R., Mahvash, A., Pracht, M., Montazeri, A.H., Bandula, S., Hermann, K., Brown, E., Zuckerman, D., Wilson, G., Kim, T-Y., Weaver, A., Ross, P., Harris, W.P., Johnson, M.S., Sofocleous, C.T., Padia, S.A., Lewandowski, R.J., Garin, E., Sinclair, P.

Volltext

59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications von Borad, M., Javle, M., Shaib, W.L., Mody, K., Bergamo, F., Harris, W.P., Damjanov, N., Macarulla, T., Brandi, G., Masi, G., Droz Dit Busset, M., Boncompagni, A., Dimova-Dobreva, M., Engelhardt, M., Saulay, M., Halfdanarson, T.R., Knox, J., Abou-Alfa, G.K., Personeni, N., Mazzaferro, V.

Volltext

45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs von Droz Dit Busset, M., Shaib, W.L., Harris, W.P., Damjanov, N., Borad, M., Vogel, A., Bridgewater, J.A., Sellmann, L., Dadduzio, V., Borner, M., Snider, J., Cantero, F., Saulay, M., Braun, S., Mazzaferro, V., Javle, M.

Volltext

47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01 von Droz Dit Busset, M., Shaib, W.L., Mody, K., Personeni, N., Damjanov, N., Harris, W.P., Bergamo, F., Brandi, G., Masi, G., Halfdanarson, T.R., Tam, V., Goff, L.W., Knox, J., Hollebecque, A., Macarulla Mercade, T., Cantero, F., Saulay, M., Braun, S., Javle, M., Borad, M.

Volltext

Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres von Chickering, D.E, Jacob, J.S, Desai, T.A, Harrison, M, Harris, W.P, Morrell, C.N, Chaturvedi, P, Mathiowitz, E

Volltext

Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications von Droz Dit Busset, M., Braun, S., El-Rayes, B., Harris, W.P., Damjanov, N., Masi, G., Rimassa, L., Bhoori, S., Niger, M., Personeni, N., Braiteh, F., Lonardi, S., Engelhardt, M., Saulay, M., Schwartz, B., Shaib, W.L., Mazzaferro, V., Papadopoulos, K.P.

Volltext

721P - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications von Droz Dit Busset, M., Braun, S., El-Rayes, B., Harris, W.P., Damjanov, N., Masi, G., Rimassa, L., Bhoori, S., Niger, M., Personeni, N., Braiteh, F., Lonardi, S., Engelhardt, M., Saulay, M., Schwartz, B., Shaib, W.L., Mazzaferro, V., Papadopoulos, K.P.

Volltext

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (I... von Abou-Alfa, G.K., Macarulla Mercade, T., Javle, M., Kelley, R.K., Lubner, S., Adeva, J., Cleary, J.M., Catenacci, D.V., Borad, M.J., Bridgewater, J.A., Harris, W.P., Murphy, A.G., Oh, D.-Y., Whisenant, J., Wu, B., Jiang, L., Gliser, C., Pandya, S.S., Valle, J.W., Zhu, A.X.

Volltext

LBA10_PR - ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydro... von Abou-Alfa, G.K., Macarulla Mercade, T., Javle, M., Kelley, R.K., Lubner, S., Adeva, J., Cleary, J.M., Catenacci, D.V., Borad, M.J., Bridgewater, J.A., Harris, W.P., Murphy, A.G., Oh, D.-Y., Whisenant, J., Wu, B., Jiang, L., Gliser, C., Pandya, S.S., Valle, J.W., Zhu, A.X.

Volltext

Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced he... von Yau, T., Merle, P., Rimassa, L., Ryoo, B.-Y., Cicin, I., Harris, W.P., Banu, E., Sarker, D., Tan, B., van Vlierberghe, H., Sen, S., Love, C., Cheng, A.-L., Meyer, T., Kelley, R.K., Abou-Alfa, G.K.

Volltext

Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patien... von Van Cutsem, E., Hendifar, A.E., Reni, M., Harris, W.P., Ducreux, M., Bullock, A., Corrie, P., Heinemann, V., Seery, T., Chondros, D., Zheng, L.

Volltext

PHOTOGRAPHIC COPYING APPARATUS von ERIC W.P. HARRIS

Volltext bestellen

Residual losses in a guard-ring micrometer-electrode holder for solid-disk dielectric specimens von Scott, A.H., Harris, W.P.

Volltext

ON A CASE OF TYPHLO-ENTERITIS von Harris, W.P.

Volltext

REPORT OF A CASE OF FISSURE OF THE ANUS von Harris, W.P.

Volltext

SEA-SICKNESS—A CURE FOR IT von Harris, W.P.

Volltext

UPS systems — static or rotary? von Harris, W.P.

Volltext